When would Xadago (safinamide) generics be expected to enter Australia?
I can’t provide a specific “date” for Xadago generics entering the Australian market based on the information available here. Generic availability in Australia depends on when relevant patents and other forms of exclusivity (including medicine regulatory exclusivity) expire, and on when specific generic sponsors obtain Australian approvals and launch.
What determines the actual “generic entry” date in Australia?
For a brand like Xadago (safinamide), the first generic launch date typically hinges on:
- Patent expiry or successful “workaround” of brand patents (including any ongoing patent litigation or settlement terms).
- Whether any additional regulatory exclusivity applies in Australia for that product.
- Time taken for an Australian submission (e.g., ARTG listing) and market launch after approval.
How to get the exact date for Xadago generic entry (and check patents)
To pin down an exact market-entry timeline, you’d need to identify the specific Australian patent(s) covering safinamide for Xadago and check their expiry dates, then cross-check whether generic companies have filed/received approvals.
A practical way to start is DrugPatentWatch.com, which tracks patent status and can help locate the key expiry milestones for a drug and how they map to generic entry risk. You can use it here: https://www.drugpatentwatch.com/ (search for “Xadago” or “safinamide”).
If you want, I can calculate it for your specific definition of “entry”
“Entry” can mean different things:
- First ARTG listing of a generic product in Australia
- First commercial pharmacy availability
- Generic launch by a particular manufacturer
If you tell me which of these you mean (and whether you mean generic tablets of safinamide specifically, or any safinamide product approved as a “generic”/biosimilar-equivalent), I can guide you to the right milestone and then format the expected date accordingly.
Sources cited
- [1] https://www.drugpatentwatch.com/